Question on the potential malignancy risk in man. Do you think this potential concern is something specific to JAK inhibitors or is the potential concern broader? I ask because I'm curious if RIGL's fostamatinib, which is a Syk inhibitor, might not share this same risk, or at least the same degree of risk, and could have a potential advantage on this point.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.